For example, DFMO, a small-molecule inhibitor of ODC, was initially approved for the treatment of Trypanosoma brucei gambiense infection and was recently approved for patients with neuroblastoma (Levin et al., 2018; Saulnier Sholler et al., 2015; Bassiri et al., 2015; Tangella et al., 2023). This evidence concerns the gene ODC1 and neuroblastoma.